Abstract 444P
Background
In 2017, SURC was introduced in Victoria Australia responding to broader contexts challenges within the health system. SURC’s a nurse led model of care addressing and identifying gaps within an oncology service to support patients experiencing SACT toxicities during the period of active treatment. In May 2020 the Symptom & Urgent Review Clinic (SURC) commenced in Ballarat’s Regional Integrated Cancer Centre. (BRICC) provides health care in the Victorian Grampians Region covering 48,646 square kilometre area. BRICC provides three outreach cancer services to Stawell, Horsham, and Maryborough.
Methods
SURC provides a streamlined process for Oncology patients receiving SACT access to dedicated oncology nursing and medical staff through a single point of access. Patients access SURC from start of treatment, throughout their SACT and 12 weeks after treatment completion. SURC contacts all C1D5 patients, patients discharged from hospital, and shared medical/nursing model of care. SURC referrals were from the medical and nursing oncology team, allied health and other internal and external stakeholders. Patients or their carer could call SURC directly. Workforce challenges in 2022 resulted in SURC setting up a mirrored service supporting BRICC patients in Stawell and Maryborough enabling them to continue having treatment close to home and have their symptoms and toxicities addressed in a timely fashion by an advanced oncology nurse. SURC also became the point of contact for any COVID-related questions and management of patients testing COVID positive.
Results
From May 2020-April 2023 there was 6558 contacts to SURC including telephone calls, clinic presentations, same day ED and day admissions. SURC funding was outpatient WASE 40.52 data activity recorded by IBA. Pre and post SURC data for admitted patients was analysed showing inpatient stay days halved from 686 to 399, reduction in inpatient oncology visits of 104 to 70, as well as readmissions from 4-0.
Conclusions
SURC has improved quality of care and access to specialist nursing and medical advice for patients receiving SACT. SURC provides a single point of access for patients receiving SACT and has also had a significant positive impact on early symptom recognition and management in a timely manner.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Grampians Health Ballarat.
Funding
Has not received any funding.
Disclosure
S. Bartlett: Non-Financial Interests, Personal and Institutional, Member of Board of Directors: CNSA.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract